5-FU and mitomycin-C in conjunction with radiotherapy in patients with locally advanced pancreatic carcinoma

To evaluate the outcome of concomitant radiocemotherapy [RCT] in terms of treatment response, tolerability, possibility of subsequent surgical resection and survival in locally advanced pancreatic carcinoma. Twenty patients with locally advanced pancreatic carcinoma had been included in a prospective study. Patients had attended to Kas El Aini Center of Clinical Oncology and to the Menoufiya University Hospital and Liver institute, between September 1998 and December 2000. All patients were treated by RCT compirising 5400 cGy daily fractions of180 cGy 5 days a week, 5-Floruracil [5-FU] : 600mg/m2 by continuous intravenous infusion day 1-day 5 and Mitomycin-C': 10mg/m[2], i.v.-bolus day 2. Chemotherapy was repeated on day 29. patients were re-evaluated for the treatment outcome and the possibility of surgical resection 4 weeks after RCT Treatment response, toxicity and overall survival were the study end point. Twelve patients [60%] had decreased primary tumor size. Five cases appeared potentially respectable by CT and exp1plorative laparotomies were done but only four could be respected. The median survival of the study group was 10 months [range 4-21]. Themedian survival of patients who had undergone surgery was 19 ms [1421] response but appeared irresistible by the CT scan. The mediam survival of patients with stationary or progressive tumors was 6.5 ms [4-10]. The treatment applied in the study is feasible and have o significant acute toxicity. The respectability was improved but with no improvement of survival. Additional neoadjuvanl chemotherapy trials with new regimens may support the potential benefits of this line of treatmen

Reversion mutation in dark variants of luminous bacteria and its application in gene toxicant monitoring / 华中科技大学学报（医学）（英德文版）

The luminous intensity of dark variant (S1) separated from photobacterium phosphoreum (A2) was 1/10,000 less than that of wild-type. Ethidium bromide (EB) (0.6 mg/L), Mytomycin C (MC, 0.05 mg/L), 2-amino fluorene (2-AF, 1.0 mg/L) all could strongly induce reversion mutation for S1 within 24 h and increase reversion ratio significantly. The results of experiments indicated that these revertants had stable genetic characteristic and the mutation may take place at gene levels. The mutagenesis to S1 caused by EB, MC and 2-AF was detected and it may be used as a new rapid, simple and sensitive method for gene toxicant monitoring.

Uso de la Milamicina C instalada, como profilaxis en la recurrencia de Pterigiones: en pacientes intervenidos quirúrgicamente en el Centro Nacional de Oftalmología

El presente estudio tiene como objetivo identificar el efecto de la Mitomicina C 0.02, instalada en el postoperatorio, en 20 pacientes escogidos al azar, con historias de 1 a 5 recurrrencias de pterigion. Los sujetosdel estudio se intervinieron entre los meses de septiembre y noviembre de 1998, con la técnica de escisión simple. En el primer día postoperatorio cada pacientes inició el uso de Mitomicina C al 0.02, una gota cada 8 horas, durante 5 días.El corte evaluativo se realizó cuando todos los pacientes tenían por lo menos 3 meses de intervenidos, 2 pacientes presentaron retardo en reepitelización conjuntiva durante las 2 primeras semanas de postoperatorio, que remitieron al final de este período. Dos pacientes presentaron recurrencia (10), teniendo estos las características de historia de más de una recidiva anterior, del grupo etáreo de25 a 34 años, además que fueron intervenido 1 año después de su ultima recurrencia. Se concluyó que el uso de Mitomicina C como porfilaxis en prevenir la recurrencia, es un método seguro y eficaz; y que los pacientes mas jovenes (grupo de 15 a 34 años), del sexo masculino, y con historia de más de recurrencia anterior, o recurrencia última de un año o menor, tienen mayor probalidad de enfrentar una nueva recidiva, aún con el uso de la profilaxis. Se recomendó preferir la técnica de escisión simple más la instalación postquirúrgica de Mitomicina C, a fin de evitar las recurrencias...

Production of a bacteriophage, a phage tail-like bacteriocin and an antibiotic by Bacillus azotofixans

Twenty-two nitrogen-fixing Bacillus azotofixans strains shown to produce an inhibition zone against themselves in plate assays. The B. azotofixans type strain P3L-5, chosen for further studies, produced inhibition zones against various Bacillus strains and other bacterial genera. This antibacterial substance was also produced in liquid medium and its production was enhanced in semisolid medium (0.4% agar) after 3 to 5 days of incubation. The substance was suggested to be an antibiotic and its preliminary characterization showed resistance to heat (100§ C, 15 minutes), to trypsin, pronase, deoxyribonuclease I, ribonuclease A, phospoholipase C, ethanol, acetone, and ether, and sensitivity to strong alkali treatment. Its molecular weight was estimated to be between 3500 to 6000. After induction of B. azotofixans P3L-5 with mitomycin C or ultraviolet light, two types of particles were detected in the lysate: one similar to a phage tail and the other, less frequent, similar to a complete bacteriophage. Lysates containing these particles showed a killing effect in some but not all B. azotofixans strains, but neither the other Bacillus species nor Micrococcus were inhibited by these lysates

Precocious desynapsis of XY-bivalent in mouse germinal cells: influence of mitomycin C on tumour-bearing and normal mice.

A comparative study on the cytotoxic potential of anticancer-antibiotic mitomycin C has been made on tumour-bearing and normal mice considering precocious desynapsis of sex bivalent as parameter. The study indicates a strikingly differential effect of the drug on the phenomenon in two different types of mice. The administration of mitomycin C at therapeutic dose although enhances the frequency of precocious desynapsis of XY-bivalent in non-tumour (normal) mice to a significant extent (compared to control), the same drug at the same dose fails to produce a similar effect on tumour-bearing specimens. Discussions have been made on: (i) the probable cause for this differential effect, (ii) the mechanism of mitomycin action on precocious desynapsis of sex bivalent and, (iii) the possible significance of the findings in relation to cancer chemotherapy.